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Background: Hypogonadism is prevalent during opioid treatment, but the effect of testosterone replacement 26 
treatment (TRT) on body composition, pain perception, and adrenal function is unclear. 27 
Purpose: To measure changes in body composition, pain perception, quality of life and adrenal function 28 
after TRT or placebo in opioid treated men with chronic non-malignant pain. 29 
Methods: Double-blind, placebo-controlled study in 41 men (>18 years) with total testosterone <12 nmol/L 30 
were randomized to 24 weeks TRT (Testosterone undecanoate injection 3 times/6 months, n=20) or placebo 31 
(placebo-injections, n=21). 32 
Outcomes: Body composition (lean body mass and fat mass assessed by DXA), clinical pain intensity 33 
(numerical rating scale), and experimental pain perception (quantitative sensory assessment), quality of life 34 
(SF36), and adrenocorticotrophic hormone (ACTH) test. Data were presented as median (quartiles). Mann 35 
Whitney tests were performed on delta values (24-0 weeks) between TRT and placebo. 36 
Results: The median age was 55 years (46; 59) and total testosterone before intervention was 6.8 (5.0; 9.3) 37 
nmol/L. TRT was associated with change of testosterone levels 12.3 (7.0; 19.9) nmol/L (p<0.001 vs. 38 
placebo), increased lean body mass 3.6 (2.3; 5.0) kg vs. 0.1 kg (-2.1; 1.5) during TRT vs. placebo and 39 
decreased total fat mass -1.2 (-3.1; 0.7) kg vs. 1.2 kg (-0.9; 2.5) kg, both p<0.003. Changed pain perception, 40 
SF36, and ACTH stimulated cortisol levels were non-significantly changed during TRT compared with 41 
placebo. 42 
Conclusions: Six months TRT improved body composition in men with opioid induced hypogonadism 43 

















Opioid medications are widely used to manage chronic non-cancer pain. Opioids are known to suppress 48 
pituitary function by inhibition of the relevant hypothalamic releasing factors via opioid receptors, which are 49 
widely distributed throughout the central nervous system (1). One of the most well described hormonal side 50 
effects of opioid treatment is male hypogonadism. Treatment with opioids increases the risk of secondary 51 
hypogonadism, characterized by low serum levels of testosterone and low levels of luteinizing hormone and 52 
follicle-stimulating hormone (2). Recent reviews estimate that the risk of hypogonadism ranges from 17 to 53 
89% in men treated with opioids (3). The risk magnitude of male hypogonadism depends on treatment 54 
duration, dosage of opioids, and the applied cut-off level for total testosterone to define hypogonadism (3). 55 
Testosterone replacement therapy (TRT) is indicated in men with severe hypogonadism, whereas the 56 
indication for TRT in opioid-induced relative hypogonadism in men is debated.  57 
 58 
The potential effect of TRT on pain perception remains to be investigated. In animal studies, the opioid and 59 
gonadal systems interact and regulate sensitivity to nociceptive stimuli (3). In castrated male rodents, 60 
testosterone administration improves pain tolerance to mechanical and thermal nociceptive stimuli (3). Few 61 
studies have investigated the effect of TRT on pain outcomes and quality of life in opioid-treated men with 62 
relative hypogonadism. A recent meta-analysis (4) found one eligible randomized controlled trial (n=84, 63 
study duration 3 months) (5) and four observational studies (total n=157) (4). The authors concluded that 64 
very low-quality evidence supported that TRT was associated with improved pain and emotional 65 
functioning, whereas TRT did not affect physical functioning, role functioning, or social functioning (4). 66 
Furthermore, sexual function is impaired during opioid treatment (6) and data regarding sexual function 67 
during TRT in these men are sparse (5). Obesity is inversely associated with testosterone levels (7). Lean 68 
body mass is positively associated with higher endogenous pain modulation (8). TRT increases lean body 69 
mass and decreases abdominal subcutaneous adipose tissue (9-11). In theory, disability may be linked to 70 
inactivity and low lean body mass and therefore, presence of chronic pain could increase the effect of TRT 71 














TRT on pain perception is mediated via improved body composition with higher lean body mass is 73 
undetermined.   74 
 75 
Secondary adrenal insufficiency is a less described side effect in opioid treated individuals (12). The 76 
prevalence of insufficient adrenal response is estimated to range between 9-29% in men and women treated 77 
with long term opioids (1, 12). Adrenal insufficiency will have an adverse effect on for example 78 
inflammatory disease, joint and muscle pain (1). Furthermore, severe adrenal insufficiency should be treated 79 
according to available guidelines. Previous studies have used a wide range of diagnostic criteria for adrenal 80 
insufficiency (12) and more data are needed regarding risk and possible predictors of adrenal insufficiency in 81 
patients treated with opioids. BMI is inversely related to cortisol responsivity (13, 14), but whether improved 82 
body composition during TRT could affect cortisol levels during the ACTH test remains to be tested.   83 
 84 
The aim of the present study was to investigate the effects of TRT on body composition, pain perception, 85 
pain sensitivity, adrenal cortisol response and quality of life in opioid treated men with relative 86 
hypogonadism.   87 
 88 
Methods 89 
Study design: The study was conducted during from August 2016 - August 2019 as a single center, 90 
randomized, placebo-controlled, double-blind, study. The study outcomes were evaluated at baseline and 91 
after six month’s (24 weeks) intervention. All participants gave written informed consent. The study was 92 
approved by The Regional Scientific Ethical Committees for Southern Denmark (S-20150004) and the 93 
Danish Health and Medicines Agency. Monitoring was performed according to good clinical practice (GCP) 94 
by the GCP unit at Odense University hospital. The trial was declared in www.clinicaltrials.gov 95 
(NCT02433730). The study was planned and approved by Danish authorities May 2015. Participants were 96 
recruited from August 2016 and onwards. The authors confirm that all ongoing and related trials for this 97 














capture tools (15) hosted at University of Southern Denmark. The study design is presented in the appendix 99 
according to the Consort checklist.  100 
 101 
Participants: The study participants were men aged >18 years with total testosterone (T-testosterone) <12 102 
nmol/L and treated with opioids for non-malignant pain disease. Inclusion criteria were at least two measures 103 
of T-testosterone < 12 nmol/L (measured between 8 and 10 o’clock in the morning), treatment with opioids 104 
for at least 3 months at a dosage corresponding to at least 50 mg morphine/day (for conversion to morphine 105 
equivalent doses, we applied https://www.oregonpainguidance.org/opioidmedcalculator/), and LH and 106 
prolactin within reference interval. Exclusion criteria were wish to conceive during the trial period, 107 
hematocrit > 53% , previous or ongoing malignant disease, prostate specific antigen (PSA) > 3 ng/dl, 108 
untreated ischemic heart or respiratory disease, alcohol or drug abuse, abnormal routine blood samples (TSH, 109 
ionized calcium, hemoglobin, liver and kidney function), treatment with 5α-reductase inhibitors and oral 110 
glucocorticoid steroids, previous or current testosterone treatment.   111 
 112 
Randomization: Randomization numbers were assigned to the participants in order of enrollment into the 113 
study. The randomization list, medicine labeling and randomization- and code break envelopes were 114 
generated by the pharmacy at Odense University Hospital to ensure double blinding. 115 
 116 
Interventions: Participants were randomly assigned to receive testosterone (TRT, testosterone undecanoate 117 
(Nebido) 1,000 mg) or placebo injections. The pharmacy at Odense University Hospital handled packaging 118 
of medicine for each study participant. Patients then received medicine according to randomization number. 119 
Placebo injections were prepared by the pharmaceutical company to ensure identical packaging of TRT and 120 
placebo. The study participants received injections at time of randomization and at 6 and 18 weeks.  121 
 122 














Participants underwent clinical examination, dual X-ray Absorptiometry (DXA) scan, assessment of clinical 124 
and experimental pain, fasting blood samples, ACTH test and OGTT and answered questionnaires by time of 125 
study inclusion and the examination program was repeated after 24-weeks intervention. 126 
 127 
Body composition measures 128 
Clinical examination included height, weight, and waist circumference.  129 
DXA: Trunk fat mass, total fat mass, fat percentage, and lean body mass were measured by DXA using a 130 
Hologic Discovery device (Waltham, MA, USA). The CV was 0.8% for total fat mass and 0.6% for lean 131 
body mass.  132 
 133 
Assessment of clinical pain parameters 134 
Data on clinical pain manifestations were collected the electronic software system PainData used in the Pain 135 
Center at the Odense University Hospital in Denmark. Data was collected on pain duration and intensity of 136 
clinical peak pain, and clinical average pain on a 0-10 numerical rating scale (NRS) with 0 defined as “no 137 
pain” and 10 “as worst imaginable pain” during the previous 24 hours. Absolute difference in NRS pain 138 
intensity was calculated as pain intensity at baseline minus pain intensity at 6 months follow-up with positive 139 
numbers indicating a reduction in pain intensity at follow-up. 140 
 141 
Assessment of experimental pain sensitivity: Participants underwent assessments of pressure pain 142 
thresholds (PPTs and cPPT) and pressure pain tolerance (PTT), a protocol for temporal summation of 143 
pressure pain (TSP), a protocol to determine pain wind-up ratio (WUR), a protocol for conditioned pain 144 
modulation (CPM), as well as assessment of heat pain thresholds (HPT) and cold pain thresholds (CPT). All 145 
pain sensitivity assessments were performed with the participant seated on a plinth with both arms resting on 146 
the thighs. The assessment lasted 30 minutes and was performed by the same experienced assessor (HBV). 147 
Pain assessment was undertaken in the same order for all participants (PPTs, cPPT, PTT, TSP, CPM, WUR, 148 















Questionnaires: The Short-Form 36 (SF-36) is a generic measure of health status comprising 36 items 151 
related to eight dimensions: physical functioning for the limitation in performing all physical activities, role 152 
physical for problems with work or other daily activities, bodily pain, general health, vitality, social 153 
functioning, role emotional, and mental health (16). QualityMetric’s Scoring Solutions and license 154 
agreements were obtained from Qualitymetric.com.  155 
Sexual function: Participants fulfilled a Danish questionnaire regarding sexual function (17). The 156 
questionnaire was developed and validated by Søren Buus Jensen (17) and included questions regarding 157 
partner status, sexual activity, and erectile dysfunction. Erectile dysfunction was defined to be present if the 158 
patient agreed to one the following statements regarding sexual intercourse and/or masturbation: I can get 159 
erection, but it disappears during intercourse/masturbation. I often have problems getting erection. It is not 160 
possible for me to get erection.   161 
We had information regarding prescription of phosphodiesterase type 5 (PDE5)-inhibitors, but we did not 162 
have information regarding actual use. Therefore, use of PDE5-inhibitors was not included in results.   163 
 164 
Oral glucose tolerance test (OGTT): A 2 hour OGTT was performed at 8:00am after overnight fasting. 165 
Blood glucose was measured at 0, 30, 60, and 120 minutes after oral ingestion of a glucose load containing 166 
the equivalent of 75 g anhydrous glucose dissolved in water. Area under the curve for glucose was calculated 167 
applying the trapezium rule. 168 
 169 
Adrenocorticotrophic hormone (ACTH) test: The ACTH test was standardized to be performed after the 170 
OGTT. An intravenous bolus of 0.25 mg Synachten (Novartis Healthcare, Copenhagen, Denmark) was 171 
administered and cortisol levels were measured at 0 and 30 minutes. Delta cortisol was defined as cortisol 30 172 
minutes – cortisol 0 minutes. We defined insufficient response to ACTH test as 30 minutes cortisol value < 173 
420 nmol/l according to the reference interval at our laboratory.  174 
 175 














Testosterone and SHBG: Testosterone levels were measured in the morning in the fasting state by liquid 177 
chromatography tandem mass spectrometry. For testosterone measurements the intra-assay coefficient of 178 
variation was 10% for total testosterone >0.2 nmol/l and 30% in the range between 0.1- 0.2 nmol/l. SHBG 179 
was measured by autoDELFIA assay and bioavailable testosterone (BioT) was calculated according to the 180 
formulas of Vermeulen (18), http://www.issam.ch/freetesto.htm. During calculations, we used the 181 
assumption that albumin concentration in participants was 4.3 g/L. The normal range and 95% confidence 182 
interval for BioT was 7.3 nmol/l (7.0 – 7.5 nmol/l) (7).  183 
Lipids: Plasma total cholesterol, high-density lipoprotein cholesterol (HDL), and triglycerides (TG) were 184 
analyzed by enzymatic colorimetric reactions (Modular P, Roche), and low density lipoprotein cholesterol 185 
(LDL) was calculated using the Friedewald equation. For fasting lipid parameters, reference intervals were 186 
as follows: total cholesterol: 3.6–6.8 mmol/l, LDL: 1.8–4.5 mmol/l, HDL: 0.76–1.68 mmol/l, and TG: 0.47–187 
2.31 mmol/l.  188 
Serum cortisol was measured using an automated solid-phase, competitive chemiluminescent enzyme 189 
immunoassay using an Immulite 2000 XPi analyzer, Siemens Healthineers. At cortisol level 290 mmol/l, the 190 
precision was CV 7.7% (SD 22.4) and at cortisol 587 nmol/l, the CV was 6.4% (SD 37.8).   191 
Blood glucose was measured with a Hemocue device (Hemocue, Ängelholm, Sweden), which converted 192 
blood glucose concentrations to equivalent plasma glucose concentrations (19). The meter was checked with 193 
a control cuvette every day and a hemolysate every 1–2 weeks. 194 
 195 
Statistical analysis 196 
By the time of study planning, no study had investigated the effect of TRT on pain perception. Therefore, the 197 
sample size of the study was determined by the effect of TRT on lean body mass based on a meta-analysis on 198 
testosterone therapy in aging men by Isidori (20). If the study had sufficient power to detect significant 199 
changes in lean body mass, we hypothesised that the study would be sufficiently powered to detect clinical 200 
relevant changes in pain perception. The inclusion of study participants and number of drop outs is presented 201 














Pre-treatment differences between participants in the testosterone and placebo group were tested using Mann 203 
Whitney U tests. The dataset was of limited size, and therefore the effects of TRT and placebo were analyzed 204 
by comparing delta (Δ) values of hormonal and metabolic variables using Mann-Whitney test as described 205 
by Altman (21). Δ-values on clinical and biochemical markers were calculated as post-treatment level minus 206 
pretreatment level. Δ-Pain sensation measures were correlated with Δ-values of total testosterone and body 207 
composition using Spearman non-parametric correlation tests.  208 
All statistics were performed using SPSS 17.0 (SPSS Inc, Chicago, USA) for calculations and p-values < 209 
0.05 were considered significant. Data are given as median and interquartile range.  210 
 211 
Results 212 
Study population (n=41) 213 
Baseline data are shown in Table 1. The two intervention groups (TRT, n=20 and placebo, n=21) were 214 
comparable at baseline regarding all clinical and biochemical study outcomes. At baseline, insufficient 215 
ACTH test was observed in 6 men (16%, 3 placebo, 3 TRT). In participants with insufficient cortisol 216 
response to the ACTH test, unstimulated cortisol levels ranged from 86-192 nmol/L and stimulated cortisol 217 
levels ranged from 372- 419 nmol/L. The median morphine equivalent dosage (ME) was 163 mg/day (range 218 
86-192 mg/day) in participants with insufficient cortisol response compared to median morphine equivalent 219 
dosage of 90 mg/day (range 45-360 mg/day) in participants with sufficient cortisol response (p=0.22 between 220 
groups).      221 
TRT vs. placebo treatment 222 
TRT was associated with higher testosterone levels (total and free testosterone), improved body composition 223 
(increased lean body mass and decreased BMI, fat trunk, total fat mass, and fat percentage), unchanged lipids 224 
(T-cholesterol, LDL, TG, HDL (HDL not shown)), and unchanged glucose levels (fasting blood glucose, 2h 225 
blood glucose and AUC glucose during OGTT) (Table 1).  226 
Changes in cortisol levels during the ACTH test (cortisol 30 min and delta cortisol) were comparable 227 
between TRT and placebo. The number of participants with insufficient cortisol response during ACTH test 228 














participants changed response pattern from sufficient to insufficient response or vice versa during the 230 
treatment period.     231 
TRT improved SF36 physical component score (PCS), whereas the remaining dimensions of SF36 and visual 232 
analogue (VAS) scores were unchanged. Changes in experimental pain sensitivity outcomes were not 233 
significantly different between TRT and placebo (Table 2).  234 
Bivariate associations between Δ-pain and Δ-body composition and Δ-testosterone levels during TRT 235 
Δ-peak NRS pain scores showed an inverse association with Δ-T-testosterone (r= 0.50, p=0.04) and Δ-Bio T 236 
(r= 0.55, p=0.02), suggesting that higher change in T-testosterone and Bio T was associated with larger 237 
reductions in peak pain intensity in the TRT group. Δ-pain measures were not significantly associated with 238 
Δ-lean body mass or Δ-fat mass (data not shown).  239 
 240 
Sexual function 241 
Baseline: A total of 23/36 men participating in the study were married (16/19 TRT vs. 12/17 placebo, p= 242 
0.43) with median marriage duration of 16 (6; 28) years and fatherhood of 2 (2; 3) children. At baseline, 243 
erectile dysfunction was present in 23/35 (65%) men (12/18 vs. 11/17, p=0.9) with no ability to obtain 244 
erection in 13/35 men (8/18 vs. 5/17, p=0.6), whereas 12/35 (6/18 vs. 6/17, p=0.56) had no erection 245 
problems. At baseline, 27/35 (13/18 vs. 14/17, p=0.34) men had coitus at intervals longer than one month 246 
with average duration since last coitus of 150 (10; 1662) days (150 (10; 2007 vs. 257 (13; 1095) days, 247 
p=0.7).    248 
TRT vs. placebo: Partner status was unchanged in all men during the study. At 6 months, erectile 249 
dysfunction was present in 14/32 men (4/16 vs. 10/16, p=0.03) with no ability to obtain erection in 10/32 250 
(3/16 vs. 7/16, p=0.10), whereas 18/32 (12/16 vs. 6/16, p=0.03) reported no erection problems. At 6 months, 251 
20/31 (9/16 vs. 11/15, p=0.32) had coitus at intervals longer than a month with average duration since last 252 
coitus of 18 (6; 1825) days in TRT vs. 365 (30; 1450) days in the placebo group (p=0.04 Δ-TRT vs. Δ-253 
placebo).    254 














In the present study, body composition improved during 6 months randomized intervention with TRT 257 
without significant changes in clinical and experimental pain perception and adrenal function in men treated 258 
with opioids for non-malignant chronic pain disease. The present study is the first long term randomized 259 
term study that investigated possible associations between improved body composition (higher lean body 260 
mass), quality of life and pain perception during TRT in a male study population treated with opioids.  261 
Body composition 262 
A median increase in lean body mass of 3.6 kg was observed during TRT, whereas fat mass decreased with 263 
median 1.2 kg. A positive effect of TRT treatment on body composition has previously been reported in 264 
other study populations (20) and change in lean body mass was our primary study outcome. According to the 265 
meta-analysis by Isidori et al (20), our power calculation was based on an expected increase in lean body 266 
mass of 1.6 kg. The meta-analysis (20) was based on randomized placebo controlled studies performed in 267 
diverse study populations and of different study duration, whereas limited data regarding change in body 268 
composition during TRT are available in opioid-induced male hypogonadism (5). Basaria et al described on 269 
average 1.0 kg increase in lean body mass during 3 month intervention with transdermal testosterone gel in 270 
opioid treated men (5). Importantly, men included in the study by Basaria et al (5) were comparable to our 271 
study population regarding inclusion criteria (both studies included opioid treated men with testosterone <12 272 
nmol/l), mean age (49 vs. 54 years), mean BMI (32 vs. 29 kg/m2) and mean daily opioid dosage (114 vs. 100 273 
mg). The findings by Basaria et al (5) supported that men with hypogonadism due to opioid treatment had 274 
similar improvement in lean body mass during TRT compared to men with hypogonadism due to other 275 
diseases (20). Post treatment total testosterone was 27.2 nmol/L in the study by Basaria et al (5) compared to 276 
19.3 nmol/L in the present study, which could support that our finding of higher gain of lean body mass 277 
could be explained by longer treatment duration of TRT and not average serum testosterone concentration. 278 
We found that fat mass decreased median 1.2 kg during TRT, which was comparable to results reported by 279 
Basaria et al (average loss in fat mass 0.8 kg) (5) and by Isidori et al (average loss of fat mass 1.6 kg) (20). 280 
The present data therefore add to the evidence that body composition is improved during TRT and the 281 
positive effect of TRT on body composition is not dependent on patient cohort but is dependent of 282 















Pain perception 285 
Measures of clinical pain intensity, experimental pain sensitivity, and measures of quality of life were 286 
unchanged during TRT in the present study, which contrasted our study hypothesis. By time of study 287 
planning, animal studies (3) and human uncontrolled studies (4) had shown improvements in pain perception 288 
and quality of life during TRT (4). Although the study size was limited, all outcomes of pain sensitivity 289 
measures were unchanged during study intervention, which did not support a placebo effect. The SF36 PCS 290 
domain was significantly increased during TRT, but all other SF36 domains, numerical rating scale (NRS) of 291 
pain and VAS score were unchanged during TRT, which did not support an overall benefit of TRT on quality 292 
of life. It is possible that the significant change in the SF36 domain PCS should be considered to be caused 293 
by chance as no other SF36 outcomes showed a trend towards significant changes. At present, the only 294 
available placebo controlled study regarding changes in pain and QoL during TRT is the study by Basaria et 295 
al (5), whereas remaining studies were uncontrolled (4). In contrast to the present study, Basaria et al 296 
reported changes in some but not all pain sensitivity measures with significantly higher changes in pressure 297 
pain threshold at the thumb and lower pain intensity after 10 pinprick stimulations at the hand after TRT, 298 
whereas changes in pressure pain threshold at the trapezius muscle, pain intensity after 1 pinprick 299 
stimulation, cold pain tolerance, self-reported clinical pain and SF-36 outcomes were not significantly 300 
different between TRT and placebo (5). As already mentioned, study participants in the study by Basaria et 301 
al (5) were comparable to the present study, but participants obtained higher serum levels of total 302 
testosterone during TRT, and the effect of TRT on lean body mass was more modest than in the present 303 
study. In accordance, in the present study the reduction in NRS peak pain was associated with Δ- 304 
testosterone, whereas changes in pain measures were not associated with changes in body composition.   305 
The findings by Basaria (5) and the present study supported that possible effects of TRT on pain modulation 306 
and Qol was mediated primarily by higher testosterone levels instead of increased lean body mass. 307 
Furthermore, it could be important to note that the study duration was 3 months in the study by Basaria et al 308 
(5) in contrast to the study duration of 6 months in the present study. It is possible that a modest positive 309 














androgen deprivation therapy in men with prostate cancer resulted in worsening of depression scores and 311 
Qol, whereas pain sensitivity and clinical pain were unchanged (22). Available data do not support any 312 
clinical significant effect of long term TRT on clinical and experimental pain, but future studies should 313 
discriminate between short and long term effects of TRT on pain modulation.   314 
 315 
Adrenal insufficiency was found in 16% men in the present study, and presence of adrenal insufficiency 316 
was associated with higher median morphine equivalent dosage. Interestingly, 30 minutes cortisol levels 317 
during the ACTH test in men with adrenal insufficiency were in all cases only moderately decreased and we 318 
found no participants with severe adrenal insufficiency. Increased risk of adrenal insufficiency in opioid 319 
treated patients have been reported in previous studies (1, 12), however, different tests were applied for 320 
adrenal function assessment (1, 12). The adrenal sensitivity for morphine treatment differs between 321 
individuals and could be due to opioid receptor polymorphisms resulting in altered opioid receptor affinity or 322 
genetic variations in interleukin 1b, a stimulator of corticotropin and corticotrophin releasing hormone 323 
(CRH) (12). We found no significant change of adrenal activity after TRT, despite significant improvements 324 
of body composition. Previous studies found an inverse association between BMI and cortisol responsivity 325 
(13, 14), but it is possible that the change of body composition in the present study was too modest to affect 326 
adrenal function. Furthermore, adrenal drive (23) and CBG levels (24) could decrease after weight loss, 327 
which could be an alternate explanation of unchanged levels of total cortisol during TRT. Insufficient 328 
adrenal function could affect quality of life and low cortisol levels could have an adverse effect on for 329 
example inflammatory disease, joint and muscle pain (1). Severe adrenal insufficiency should be treated 330 
according to available guidelines, but the possible benefits of treating more mild adrenal insufficiency with 331 
hydrocortisone regarding quality of life and pain perception remains to be evaluated in future studies.  332 
 333 
Sexual function: Sexual function was significantly improved during TRT as erectile dysfunction improved 334 
and sexual activity increased. These data supported the findings by Basaria (5) who reported significantly 335 
greater increase in sexual desire during TRT, whereas they found no differences in orgasmic domain and 336 














erectile dysfunction, and 37% of participants were not able to have erection. Impaired sexual function in 338 
opioid treated men is well described (6). Present data support that sexual function is improved but not fully 339 
restored during TRT, which could be due to unchanged pain perception during TRT.     340 
 341 
Strengths and limitations may apply in the present study. The trial was double blind and placebo controlled 342 
with only few drop outs. The primary study outcome was lean body mass, whereas the study could be 343 
underpowered to detect minor changes in secondary study outcomes such as pain perception. However, the 344 
use of multiple standardized assessments for pain, pain threshold and tolerance is an important strength of 345 
the study as the use of a single assessment can lead to questions of reliability. The study was planned during 346 
2014-2015 and by this time, the placebo controlled study by Basaria et al was not published (5). Therefore, 347 
the power calculation could not be based on their results. Our study was sufficiently powered regarding our 348 
primary study outcome, however the study could be underpowered to detect minor changes in pain and 349 
quality of life outcomes. We did not include information about smoking, alcohol and other lifestyle factors, 350 
which could have changed during study intervention and could have affected our study results. Several study 351 
outcomes were addressed and therefore the issue of multiple testing needs to be discussed. We could 352 
categorize the study outcomes into a limited number of aspects including body composition (weight, lean 353 
body mass, total and regional fat mass), measures of pain perception and quality of life (objective 354 
measurements and questionnaires) and adrenal function (ACTH test). The use of several screening 355 
modalities for each study outcome strengthened the study conclusion.  356 
 357 
Conclusion 358 
Six month TRT improved body composition without significant changes in pain perception, pain sensitivity 359 
and quality of life in men with relative opioid induced hypogonadism.   360 
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Table 1: Clinical characteristics, quality of life and adrenal function at baseline and 6 months follow-up in 
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Table 2: Experimental pain sensitivity at baseline and 6 months follow-up in the TRT and placebo groups. 















Peak Pain numerical rating scale 8.0 (7.0; 8.8) 9.0 (7.0; 10.0) 7.0 (6.0; 8.5) 8.0 (6.3; 8.0) -0.5 (-1.0; 0.0) 0.3 (-0.8; 1.8) 0.13 
Average Pain numerical rating scale  6.0 (4.3; 7.0) 6.0 (5.0; 8.0) 5.0 (4.0; 6.5) 5.0 (3.3; 6.0) -0.2 (-0.5; 0.0) 0.45 (0.0; 1.8) 0.18 
Heat pain threshold  (°C) 44.5 (40.2; 46.5) 43.3 (39.2; 47.3) 41.1 (38.3; 45.7) 42.6 (39.4; 46.5) -0.3 (-2.5; 1.8) 0.8 (-2.3;3.4) 0.45 
Cold pain threshold  (°C) 11.9 (5.1; 20.6) 13.8 (5.7; 20.8) 10.0 (5.0; 17.9) 12.3 (6.6; 15.3) 1.7 (-2.9;6.3) 0.4 (-1.2;2.5) 0.80 
Pressure pain thresholds (kPa) 372 (292; 530) 355 (211; 387) 314 (233; 443) 310 (252; 430) -58 (-163;53) -2 (-71;59) 0.25 
Cuff pressure pain threshold (kPa) 20.5 (16.0; 28.2) 20.5 (15.2; 29.1) 22.2 (14.0; 26.0) 21.4 (16.6; 25.8) -1.3 (-6.5;4.3) 2.1 (-2.3;5.6) 0.12 
Cuff pressure pain tolerance (kPa) 45.0 (30.9; 59.7) 42.9 (30.5; 80.0) 44.0 (31.8; 52.9) 47.1 (30.9; 52.9) -3.6 (-14.3;2.6) 0.1 (-5.3;4.7) 0.29 
Cuff-induced temporal summation of pressure pain (ratio) 2.2 (1.5; 2.6) 1.9 (1.4; 2.5) 1.9 (1.2; 2.9) 1.7 (1.3; 3.5) 0.5 (-0.9;1.2) -0.1 (-1.5;1.5) 0.75 
Wind-up ratio 2.0 (0.5; 3.0) 3.0 (1.0; 5.3) 1.0 (0.0; 2.0) 1.5 (0.0; 2.3) 0.6 (-1.0;1.0) 0.9 (0.0;2.0) 0.46 
Conditioned pain modulation (kPa) 6.8 (1.0; 16.1) 4.2 (-1.4; 14.3) 7.5 (3.8; 11.9) 6.9 (1.5; 10.3) -2.5 (-6.7;5.1) -1.2 (-8.8;5.0) 0.52 
 
Data presented as median (quartiles)  
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Data presented as median (quartiles)  
P-value represents unpaired Mann Whitney test on changes (delta values) during intervention with testosterone vs. placebo 
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